Information & Dosing

General Information

Peptides are shipped as a dry, fluffy powder because they are not stable in liquid form at room temperature. This freeze-dried state is called lyophilized. Before you can use the peptide, you must reconstitute it by adding bacteriostatic water — sterile water containing 0.9% benzyl alcohol. The benzyl alcohol prevents bacterial growth, so the solution stays safe and stable for multiple draws over roughly 30 days.

The Classic Example

A 10 mg vial + 1 mL of bacteriostatic water gives a concentration of 10 mg/mL. On a standard 100-unit insulin syringe (where 100 units = 1 mL), every 10 units drawn equals 1 mg of peptide. That is the most common starting ratio used in research protocols.

Other Common Mixing Ratios

Adding more water lowers the concentration and makes each unit a smaller dose — useful for precise microgram dosing. Adding less water raises the concentration but can make small doses harder to measure accurately.

Step-by-Step

Why Bacteriostatic Water?

• Preservation: the 0.9% benzyl alcohol stops most bacteria from growing once the vial is punctured.
• Shelf life: reconstituted peptides kept refrigerated generally remain stable for about 30 days with BAC water.
• Avoid sterile water: plain sterile water has no preservative and should only be used for single-draw applications.
• Never use tap or distilled water: both can introduce contamination and rapidly degrade the peptide.

General Information

Retatrutide is a once-weekly investigational triple hormone receptor agonist activating GIP, GLP-1, and glucagon receptors. Developed by Eli Lilly, it is being studied for obesity, type 2 diabetes, and metabolic disease. The triple-mechanism design targets appetite, satiety, and energy expenditure simultaneously.

Reconstitution

• • Inject bacteriostatic water slowly down the inside wall of the vial.
• • Swirl gently until the peptide fully dissolves. Do not shake.
• • Solution should be clear. Discard if cloudy, particulate, or discolored.
• • Refrigerate at 35–46 °F after mixing; use within ~30 days. Lyophilized vials keep 24+ months frozen.

Sub-Q Dosing Protocol

Inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites weekly. Dose increases should be gradual to minimize nausea and GI side effects. Many research protocols stop titration if tolerability limits are reached.

What the Studies Show

• Weight loss: Phase 2 trials (SURMONT-1) reported mean weight reductions of 8–24% depending on dose over 48 weeks, with the highest dose showing the greatest effect.
• Metabolic markers: improvements in HbA1c, fasting glucose, insulin, and triglycerides have been observed in people with obesity and type 2 diabetes.
• Mechanism: combined GIP/GLP-1/glucagon agonism suppresses appetite, delays gastric emptying, and increases energy expenditure — the triple action is thought to drive superior outcomes versus single-agonist drugs.
• Cardiovascular: early exploratory data show reductions in blood pressure and liver fat, with larger cardiovascular outcome trials ongoing.
• Side effects: the most common are GI (nausea, vomiting, diarrhea, constipation) and are dose-dependent. Gallbladder-related events and pancreatitis have been monitored but are not yet conclusively quantified.
• Status: Retatrutide is investigational and not FDA-approved for any indication. All dosing is for research modeling only.

General Information

Tirzepatide is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, and is widely studied for glycemic control, weight loss, and metabolic risk reduction.

Reconstitution

• • Inject bacteriostatic water slowly down the inside wall of the vial.
• • Swirl gently until the peptide fully dissolves. Do not shake.
• • Solution should be clear. Discard if cloudy, particulate, or discolored.
• • Refrigerate at 35–46 °F after mixing; use within ~30 days. Lyophilized vials keep 24+ months frozen.

Sub-Q Dosing Protocol

Inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites weekly. Dose escalation is typically scheduled every 4 weeks based on tolerability. Many research protocols hold or reverse the dose if significant nausea, vomiting, or gallbladder symptoms occur.

What the Studies Show

• Weight loss: SURMOUNT trials reported mean weight reductions of 15–21% at the highest maintenance doses over 72 weeks in adults with obesity.
• Glycemic control: SURPASS trials in type 2 diabetes showed HbA1c reductions of 1.8–2.6% and meaningful fasting glucose improvement versus placebo and active comparators [4](https://www.nejm.org/doi/full/10.1056/NEJMoa2107519).
• Mechanism: dual GIP/GLP-1 agonism enhances insulin secretion in a glucose-dependent manner, suppresses appetite, delays gastric emptying, and increases satiety signaling.
• Cardiometabolic: exploratory analyses suggest improvements in blood pressure, lipid profiles, and waist circumference, with larger cardiovascular outcome trials ongoing.
• Side effects: the most common are GI (nausea, diarrhea, vomiting, constipation) and are dose-dependent. Gallbladder disease, pancreatitis, and hypoglycemia risk have been monitored.
• Status: Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management under brand names, but compounded or research-grade use follows different regulatory rules. All dosing here is for research modeling only.

General Information

Glutathione (GSH) is a tripeptide of cysteine, glycine, and glutamate produced in every cell. It is the body's primary intracellular antioxidant, recycling vitamins C and E, neutralizing reactive oxygen species, and driving phase II liver detoxification. Levels decline with age, oxidative stress, and illness.

Reconstitution

• • Inject water slowly down the vial wall — never spray directly on powder.
• • Swirl gently until clear. Do not shake; GSH is a fragile peptide.
• • Solution should be clear to pale yellow. Discard if cloudy or brown.
• • Refrigerate at 35–46 °F after mixing, protected from light; use within ~30 days. Lyophilized vials keep 24+ months frozen.

Sub-Q Dosing Protocol

Rotate injection sites (abdomen, thigh, flank). Evening administration is common to align with overnight repair. Many protocols cycle 8–12 weeks on, 2–4 weeks off.

What the Studies Show

• Bioavailability: oral GSH is largely degraded in the gut; parenteral routes (sub-q, IM, IV) raise plasma and erythrocyte GSH far more reliably (Witschi et al., 1992).
• Oxidative stress: repletion trials report lowered lipid peroxidation and 8-OHdG, with improved GSH:GSSG ratio (Richie et al., 2015 — sustained repletion of body stores).
• Liver & metabolic: studies in fatty liver disease show improved ALT and triglycerides with glutathione therapy (Honda et al., 2017).
• Neurology: parenteral glutathione in Parkinson's showed symptom improvement in early trials, though a randomized trial (Mischley et al., 2017) found effects near placebo — evidence is mixed.
• Skin: controlled trials report reduced melanin index and brightening with sustained dosing (Weschawalit et al., 2017).
• Safety: generally well tolerated; reported effects are injection-site irritation and transient nausea. Sub-q dosing is not FDA-approved.

General Information

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) bound to a copper ion. It acts as a copper carrier, regulating tissue repair, collagen remodeling, antioxidant defense, and gene expression. Plasma levels fall sharply with age, making it a focus of longevity and regenerative research.

Reconstitution

• • Inject bacteriostatic water slowly down the glass wall.
• • Swirl gently — never shake — until the copper peptide fully dissolves.
• • Solution should be clear blue. Cloudiness or particles mean contamination.
• • Refrigerate at 35–46 °F after mixing; use within ~30 days. Lyophilized vials keep 24+ months frozen.

Sub-Q Dosing Protocol

Rotate injection sites (abdomen, thigh, deltoid). Many protocols run 4–6 weeks on followed by 2–4 weeks off. Splitting the daily dose into two injections is common for higher targets.

What the Studies Show

• Discovery: GHK was isolated by Pickart in 1973 from human plasma albumin; its copper-bound form is the tissue-active variant.
• Skin remodeling: in vitro and human studies report increased collagen, elastin, and glycosaminoglycan synthesis, plus improved skin density and wrinkle reduction (Pickart et al., 2015).
• Wound healing: animal models show faster wound closure, angiogenesis, and improved granulation tissue with GHK-Cu (A. Pickart, 1994; S. A. Canapp et al., 2003).
• Gene expression: GHK has been reported to reset expression of 4,000+ human genes, including pathways tied to inflammation, DNA repair, and tissue remodeling (Pickart et al., 2017).
• Anti-inflammatory: reduced TNF-α and NF-κB signaling have been observed in tissue models, suggesting broader immunomodulatory effects.
• Hair growth: copper peptide-containing formulations have been studied for follicle size and anagen maintenance in hair research models.
• Safety: GHK-Cu is generally regarded as low-toxicity, but copper overload can occur at excessive doses. Mild injection-site redness or itching has been reported. Sub-q use is not FDA-approved.

General Information

KPV (Lysine-Proline-Valine) is a short tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH). Unlike full-length α-MSH, KPV lacks the melanogenic effects but retains potent anti-inflammatory and immunomodulatory activity. It is widely studied for gut barrier integrity, colitis, skin inflammation, and immune regulation.

Reconstitution

• • Inject bacteriostatic water slowly down the inside wall of the vial.
• • Swirl gently until the peptide fully dissolves. Do not shake.
• • Solution should be clear. Discard if cloudy, particulate, or discolored.
• • Refrigerate at 35–46 °F after mixing; use within ~30 days. Lyophilized vials keep 24+ months frozen.

Sub-Q Dosing Protocol

Inject subcutaneously into the abdomen, thigh, or upper arm, rotating sites daily. Many protocols run 4–8 weeks on followed by 2–4 weeks off, or pulse higher doses during active flares. Doses are typically measured in micrograms (mcg), not milligrams.

What the Studies Show

• Anti-inflammatory mechanism: KPV downregulates pro-inflammatory cytokines including TNF-α, IL-6, and IL-1β, and reduces NF-κB signaling in immune and epithelial cells.
• Colitis / IBD: animal models of colitis show reduced inflammation, improved histology, and better mucosal healing when KPV is administered systemically or locally (Brzoska et al., 2008; Luger et al.).
• Gut barrier: KPV has been reported to strengthen tight-junction proteins and reduce intestinal permeability in models of leaky gut and inflammatory bowel disease.
• Skin inflammation: as an α-MSH derivative, KPV has been studied for dermatitis, psoriasis-like models, and UV-induced skin damage through anti-inflammatory and immunomodulatory pathways.
• Autoimmune: early research suggests KPV may modulate T-cell activity and reduce tissue-specific autoimmune inflammation, though human data remain limited.
• Safety: KPV is generally considered well-tolerated in preclinical research; mild injection-site redness or irritation has been reported. Sub-q use is not FDA-approved.